Physician profile
Puja Singh
NPI 1558565911
$1,968.77
in general payments reported to CMS, 2019-2025
25 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $132 · 2021: $134 · 2022: $173 · 2023: $26.48 · 2024: $361 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $758 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $758.01 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $473.97 | 2019-2025 | Ozempic, Sogroya, Rybelsus |
| Astellas Pharma US INC | $202.49 | 2019-2025 | Veozah |
| Amgen INC. | $184.18 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $169.15 | 2019-2025 | Qulipta |
| Astrazeneca Pharmaceuticals Lp | $131.50 | 2019-2024 | Airsupra |
| Glaxosmithkline, LLC. | $121.18 | 2024 | Shingrix |
| Lilly USA, LLC | $109.62 | 2019-2025 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.21 | 2019 | |
| Biosense Webster, INC. | $63.74 | 2025 | Qdot Micro |
| Takeda Pharmaceuticals U.S.A., INC. | $55.84 | 2019-2022 | |
| Pfizer INC. | $51.41 | 2019-2021 | |
| Vivus LLC | $35.25 | 2019 | |
| Shire North American Group INC | $33.33 | 2019 | |
| Amarin Pharma, INC. | $31.46 | 2019-2021 | |
| Eisai INC. | $30.79 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $27.08 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $26.88 | 2019-2025 | Zoryve |
| Neurocrine Biosciences, INC. | $24.31 | 2025 | |
| Sumitomo Pharma America, INC. | $22.32 | 2024 | Gemtesa |
| Esperion Therapeutics, INC. | $17.13 | 2025 | Nexletol |
| Dynavax Technologies Corporation | $13.82 | 2022 | |
| Currax Pharmaceuticals LLC | $13.19 | 2020 | |
| Allergan, INC. | $12.23 | 2019 | |
| Merck Sharp & Dohme LLC | $12.04 | 2019 | |
| Dexcom, INC. | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puja Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.